SH003 Inhibits Proliferation and Induces Apoptosis in Colon Cancer Through the RTK-STAT3 Pathway

Area of Science:

• Oncology
• Pharmacology
• Herbal Medicine

Background:

• Colon cancer presents high incidence and mortality, necessitating novel therapeutic strategies beyond chemotherapy.
• Existing treatments offer limited survival benefits for advanced colon cancer.
• SH003, a herbal mixture, shows potential anticancer properties.

Purpose of the Study:

• To investigate the anticancer effects of SH003 on colon cancer cell lines.
• To evaluate the efficacy and safety of SH003 in a colon cancer xenograft mouse model.
• To explore the molecular mechanisms underlying SH003's anti-colon cancer activity.

Main Methods:

• In vitro: Assessed cell viability, apoptosis, cell cycle progression, and RTK-STAT3 pathway disruption in human colon cancer cell lines.
• In vivo: Utilized an HCT116 xenograft mouse model to evaluate tumor growth inhibition and systemic toxicity.
• Analyzed key proteins involved in apoptosis, cell cycle regulation, and the RTK-STAT3 pathway.

Main Results:

• SH003 exhibited time-dependent cytotoxicity across multiple colon cancer cell lines.
• Confirmed apoptosis induction via increased cleaved PARP and caspase levels.
• Observed G1/S phase cell cycle arrest and disruption of the RTK-STAT3 pathway (reduced ALK and STAT3 phosphorylation).
• SH003 significantly inhibited tumor growth in vivo without significant systemic toxicity.

Conclusions:

• SH003 demonstrates potent anticancer effects against colon cancer through apoptosis induction, cell cycle arrest, and RTK-STAT3 pathway inhibition.
• In vivo studies validate SH003's efficacy and safety as a potential therapeutic agent for colon cancer.
• Further research is recommended to fully elucidate SH003's mechanisms and clinical potential.